Executive record

Mark Lowdell, PhD

Public governance roles and source-backed Claims for this individual.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:mark-lowdell-phdVersion: public-0As of: 2026-09-30

Not yet claimed6 published Claims1 sources

Key Claims

Biography

Professor at University College London since 1994 leading translational immunotherapy group and cGMP cell manufacturing facility. Director of Cellular Therapy at Royal Free London NHS Foundation Trust from 2009 until retirement in 2022, with PhD in clinical immunology and expertise in cellular therapies.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Executive career

  1. 2026 to end not publishedExecutive title: Chief Scientific Officer · Organization not publishedINMB DEF 14A executive officers

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

1 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. INMB DEF 14A executive officers

    sec filing · Source published: Apr 23, 2026 · Retrieved: May 16, 2026

    Supports 6 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Inmune Bio, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Chief Scientific Officer · Claim reviewed: May 16, 2026
    • Other Company Role: Mark Lowdell, PhD is also linked to University College London as Professor of Cell and Tissue Therapy. · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026